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Body weight is negatively associated with direct oral anticoag-
ulant trough concentrations in dabigatran and apixaban users
Direct oral anticoagulants (DOACs, i.e. dabigatran, apixaban,
edoxaban and rivaroxaban) are prescribed in fixed-dose regi-
mens to treat and prevent thrombosis.1 The market autho-
rization holders state that routine monitoring of plasma
concentrations of DOACs is not required. However, clinical
studies indicate that DOAC trough concentrations are associ-
ated with both bleeding and thrombosis.2-5 A wide variability
in DOAC trough concentrations between patients is observed
and can be caused by patient factors such as age, sex, renal
function, interacting drugs and body weight or body mass
index (BMI) as described in the summary of product charac-
teristics.
To date, guidelines advise to be cautious with prescribing
DOACs to patients with extreme body weights.6 Patients with
obesity may have low DOAC trough levels and be at risk for
thrombosis,7-9 while underweight patients may be at risk for
bleeding.5,9 However, data about the association between
body weight and DOAC trough concentrations are contradic-
tory: some studies show that body weight is associated with
DOAC trough concentrations3,4,10 while other studies do
not.11 With a rising prevalence of obesity, evidence whether
body weight and DOAC trough levels are associated is crucial
for the treatment of these patients.1,7 Therefore the aim of
this study was to determine the association between body
weight and trough concentrations of all registered DOACs.
We performed a cross-sectional study and included 148 in-
and outpatients who used a DOAC for at least five days (99
male, 67%; 49 female, 33%) from the Haga Teaching Hospital,
with a mean body weight of 88 kg (standard deviation 18).
Patients were excluded if they received an off-label dosage, had
an estimated glomerular filtration rate <50 ml/min or used
interacting medications. Patient characteristics were similar in
the four treatment groups (Table SI). All patients had to pro-
vide written informed consent before starting the study. Ethi-
cal approval was obtained by the local ethics committee and
the study was conducted according to the Declaration of Hel-
sinki (version October 2013). Blood samples were collected
prior to the administration of the DOAC to determine DOAC
trough concentrations, which were measured using a validated
liquid chromatography–mass spectrometry/mass spectrometry
assay. Quantification of trough concentrations expressed as
anti-FXa activity (rivaroxaban, apixaban or edoxaban) or anti-
FIIa (dabigatran) activity was performed by a validated chro-
mogenic assay. DOAC trough concentrations and anti-FXa
activity or anti-FIIa activity values were converted to standard
doses using mean half-lives and assuming linear kinetics. The
standard doses were dabigatran 150 mg twice daily, apixaban
5 mg twice daily, edoxaban 60 mg once daily and rivaroxaban
20 mg once daily. We used multivariable linear regression to
estimate the association between body weight, BMI and DOAC
trough concentrations with 95% confidence intervals (CIs)
and adjusted for age and sex, and furthermore stratified by sex.
The univariable analysis showed a significant negative
association between body weight and dabigatran concentra-
tions (073 ng/ml/kg, 95%CI 135 to 011) and body
weight was negatively associated with apixaban concentra-
tions (045 ng/ml/kg, 95%CI 138 to 047), while results
were around unity among edoxaban (010 ng/ml/kg, 95%
CI 025 to 004) and rivaroxaban (002 ng/ml/kg, 95% CI
034 to 031) users (Fig 1 and Table SII). After adjustment
for sex and age, the associations remained similar for dabiga-
tran and were less pronounced or similar for the other three
DOACs. Results were similar when considering anti-FXa
activity or anti-FIIa activity as the outcome as compared
with DOAC concentrations (Table SII).
Similar results were found for BMI on all outcomes
(DOAC trough concentrations, anti-Fxa activity or anti-FIIa
activity, see Table SII). After stratifying by sex, more pro-
nounced regression coefficients (Fig 1) were found in female
patients as compared with male patients. This last association
was the strongest in female dabigatran patients.
The negative association between body weight and dabi-
gatran trough concentrations suggests that increasing body
weight results in lower dabigatran trough concentrations.
Distribution of medications through the body is dependent
on the lipophilicity of the drugs,12 which is expressed as
log P, where high log P values indicate high lipophilicity
of drugs. DOACs have been reported as moderately lipo-
philic13 with edoxaban as the least lipophilic (log P 090
to 161), followed by rivaroxaban (log P 174 to 190),
apixaban (log P 183 to 222) and finally dabigatran with
the highest lipophilicity (log P 459 to 517).14 As a result
dabigatran is most likely to distribute to adipose tissue,
which correspond with our findings that dabigatran con-
centrations decreased most with increasing body weight,
whereas this association was less pronounced for the other
DOACs. An additional explanation for our results may be
that the renal clearance of dabigatran is higher than for
other DOACs12 and renal function could increase due to a
increase in body weight.15 This may result in lower
correspondence
ª 2020 British Society for Haematology and John Wiley & Sons Ltd doi: 10.1111/bjh.17009
dabigatran trough concentrations, which was also reported
by Graves et al.7
For the other three DOACs, there was no statistically signifi-
cant negative association. Risk estimates were around unity for
edoxaban and rivaroxaban, whereas we found a negative asso-
ciation of body weight and BMI with unadjusted apixaban
concentrations. This finding is in line with results of Upreti
et al., who observed a negative association between body
weight and plasma anti-factor Xa activity in apixaban users.10
An unexpected finding was a stronger association between
body weight or BMI and DOAC trough concentrations in
female patients as compared with male patients, with the
exception of apixaban. These results indicate that pharma-
cokinetics of DOACs may vary between male and female
patients, which indicatesd that the DOAC dosages may need
different adjustments in female patients as compared with
male patients with extreme body weights.
This study showed that body weight and BMI are nega-
tively associated with dabigatran and apixaban trough con-
centrations and anti-FXa activity or anti-FIIa activity. The
negative association between body weight or BMI and the
dabigatran trough concentration was strongest in female
patients, which indicates that dabigatran dosages may need
adjustment in (female) patients with extreme body weights.
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Fig 1. Association between body weight (kg) and direct oral anticoagulant (DOAC) trough concentration (ng/ml): (A) apixaban, (B) rivaroxaban,
(C) edoxaban and (D) dabigatran. ]
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